Advanced cell-derived drug delivery systems for pulmonary diseases: from bench to bedside

用于肺部疾病的先进细胞衍生药物递送系统:从实验室到临床

阅读:3

Abstract

Nowadays, pulmonary diseases (PDs) are among the leading causes of mortality worldwide. Conventional therapeutic approaches exhibit disappointing efficacies due to difficulty in drug delivery and systemic cytotoxicity. In recent years, novel formulations of therapeutic drugs rised as alternatives for clinical treatment. Among them, cell-derived drug delivery systems (CDDSs) have garnered attention for their potential in treating PDs. By harnessing the innate migratory capabilities, barrier-crossing potential, high biocompatibility, and substantial drug-loading capacity of cell derivatives, CDDSs offer a promising approach for PD treatment. However, there was no systemic report in summarizing CDDSs in PDs. In this review, We first examined the biological properties and therapeutic advantages of various CDDSs in the context of PDs, including red blood cells (RBCs), stem cells, platelets, macrophages, neutrophils, tumor cells, microalgae, extracellular vesicles (EVs) and biomimetic cell membrane. We then discussed common preparation strategies and different modification methods of CDDSs. Finally, we summarized the current therapeutic advancements of CDDSs in multiple PDs. We hope this review serves as a valuable reference for utilizing CDDSs in the treatment of PDs and other diseases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。